Cogent Biosciences
COGT
30.14
-0.24
-0.79%
Cogent Biosciences
US · COGT
#2052 by market cap
Listed 2016
30.14
-0.24
-0.79%
Live - 5344 symbols - heartbeat 503s ago
· 2026-10-08 04:11
Pre-market
30.24
+0.33%
After-hours
30.14
0.00%
- Market cap
- 5.23B
- P/E (TTM)i
- -13.95
- P/Bi
- 11.18
- EPSi
- -2.16
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on COGT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.1 percentage points.
Institutional ownership
- Held by institutions
- 117.19% -2.12pp
- Institutions
- 389 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund75.22%
Hedge Fund29.14%
VC/PE Fund8.20%
Public Company3.01%
Private Company0.57%
Individual/Insider0.56%
Government Pension Fund0.45%
Sovereign Wealth Fund0.31%
Insurance Company0.28%
Top holders as of 2026-06-30
FMR
14.80% · 25.68M sh
BlackRock
10.00% · 17.35M sh
Vanguard Capital Management, LLC
4.97% · 8.63M sh
Vanguard Portfolio Management, LLC
4.65% · 8.07M sh
State Street Global Advisors
4.01% · 6.96M sh
Janus Henderson Group plc
3.82% · 6.62M sh
Fairmount Funds Management LLC
3.19% · 5.54M sh
Commodore Capital LP
3.11% · 5.40M sh
Point72 Asset Management, L.P.
3.03% · 5.26M sh
Deerfield Management Company, L.P.
2.88% · 5.01M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | 0.27% |
| Cole Pinnow | Chief Commercial Officer | 0.10% |
| John Robinson | Chief Scientific Officer | 0.05% |
| Jessica Sachs | Chief Medical Officer | 0.05% |
| John Green | Chief Financial Officer | 0.05% |
| Evan Kearns | Chief Legal Officer | 0.04% |
| Arlene Morris | Independent Director | -- |
| Matthew Ros | Independent Director | -- |
| Todd Shegog | Independent Director | -- |
| Karen Jean Ferrante | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +759 | $31.59 |
| 2026-08-26 | Arlene Morris | Independent Director | Derivative Exercise and Sale | -45,510 | $2.52–37.54 |
| 2026-06-30 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +627 | $38.48 |
| 2026-06-08 | Arlene Morris | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Matthew Ros | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Todd Shegog | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Christopher Cain | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Peter Harwin | Independent Chairperson | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-05-18 | Andrew Robbins | Chief Executive Officer | Other Acquisition | +160,000 | -- |
| 2026-05-18 | Andrew Robbins | Chief Executive Officer | Other Disposition | -160,000 | -- |
| 2026-03-31 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +686 | $35.24 |
| 2026-03-30 | Fairmount Funds Management LLC | -- | Derivative Exercise and Sale | -7,000,000 | $34.66 |
| 2026-01-21 | Fairmount Funds Management LLC | -- | Private Disposition | -3,500,000 | $36.40 |
| 2025-12-31 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +643 | $34.74 |
| 2025-12-25 | John Green | Chief Financial Officer | Open Market Disposition | -77,000 | $38.68 |
| 2025-12-25 | Evan Kearns | Chief Legal Officer | Open Market Disposition | -65,000 | $38.70 |
| 2025-12-25 | Jessica Sachs | Chief Medical Officer | Open Market Disposition | -82,642 | $38.70 |
| 2025-12-25 | John Robinson | Chief Scientific Officer | Open Market Disposition | -90,000 | $38.74 |
| 2025-12-16 | Andrew Robbins | Chief Executive Officer | Sale to Issuer | -367,497 | $39.45 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:11:05 · For reference only, not investment advice and not tailored to your situation.